What's Going On With Actinium Pharmaceuticals Stock?

Actinium Pharmaceuticals Inc ATNM shares are trading higher Tuesday after the company announced full data results from the pivotal Phase 3 SIERRA trial in patients with active, relapsed or refractory acute myeloid leukemia.

What Happened: Over the weekend, Actinum said Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission with high statistical significance. 22% of patients achieved dCR in the Iomab-B arm compared to zero in the control arm.

Additionally, Iomab-B produced a significant and clinically meaningful improvement in the secondary endpoint of Event-Free Survival, with a 78% reduction in the probability of an event.

Actinium presented the full results Saturday evening at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood & Marrow Transplant Research.

Following the presentation, HC Wainwright & Co reiterated Actinium with a Buy and maintained a $53 price target and William Blair downgraded Actinium from Outperform to Market Perform.

See Also: Why BioCryst Pharmaceuticals Stock Is Sliding Today

ATNM Price Action: Actinium shares surged higher in early premarket trading before pulling back.

The stock was up 7.56% at $14.80 at time of publication, according to Benzinga Pro.

Photo: StockSnap from Pixabay.